CoChat
Sign Up
Cited by 254Thyroid Disorders and TreatmentsOphthalmology and Eye DisordersThyroid and Parathyroid Surgery

Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis

Wiersinga, Wilmar M, Poppe, Kris G, Effraimidis, Grigoris·2023·The Lancet Diabetes & Endocrinology
DOI 10.1016/s2213-8587(23)00005-0
Open this paper in CoChat — free account

Abstract

Hyperthyroidism is a common condition with a global prevalence of 0·2-1·3%. When clinical suspicion of hyperthyroidism arises, it should be confirmed by biochemical tests (eg, low TSH, high free thyroxine [FT4], or high free tri-iodothyonine [FT3]). If hyperthyroidism is confirmed by biochemical tests, a nosological diagnosis should be done to find out which disease is causing the hyperthyroidism. Helpful tools are TSH-receptor antibodies, thyroid peroxidase antibodies, thyroid ultrasonography, and scintigraphy. Hyperthyroidism is mostly caused by Graves' hyperthyroidism (70%) or toxic nodular goitre (16%). Hyperthyroidism can also be caused by subacute granulomatous thyroiditis (3%) and drugs (9%) such as amiodarone, tyrosine kinase inhibitors, and immune checkpoint inhibitors. Disease-specific recommendations are given. Currently, Graves' hyperthyroidism is preferably treated with antithyroid drugs. However, recurrence of hyperthyroidism after a 12-18 month course of antithyroid drugs occurs in approximately 50% of patients. Being younger than 40 years, having FT4 concentrations that are 40 pmol/L or higher, having TSH-binding inhibitory immunoglobulins that are higher than 6 U/L, and having a goitre size that is equivalent to or larger than WHO grade 2 before the start of treatment with antithyroid drugs increase risk of recurrence. Long-term treatment with antithyroid drugs (ie, 5-10 years of treatment) is feasible and associated with fewer recurrences (15%) than short-term treatment (ie, 12-18 months of treatment). Toxic nodular goitre is mostly treated with radioiodine (131I) or thyroidectomy and is rarely treated with radiofrequency ablation. Destructive thyrotoxicosis is usually mild and transient, requiring steroids only in severe cases. Specific attention is given to patients with hyperthyroidism who are pregnant, have COVID-19, or have other complications (eg, atrial fibrillation, thyrotoxic periodic paralysis, and thyroid storm). Hyperthyroidism is associated with increased mortality. Prognosis might be improved by rapid and sustained control of hyperthyroidism. Innovative new treatments are expected for Graves' disease, by targeting B cells or TSH receptors.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(23)00005-0

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The patient's proximal predominant weakness with greater functional impairment in the upper extremities (2/5 proximally) on formal neurological examination differs from the classic lower limb predominant or ascending pattern typically described in TPP, expanding the recognized clinical spectrum.

    “Third, the proximal predominant weakness with greater functional impairment in the upper extremities (2/5 proximally) on formal neurological examination differs from the classic lower limb predominant or ascending pattern typically described in TPP, expanding the recognized clinical spectrum of this condition [9].”

    From Iatrogenic Thyrotoxicosis and Corticosteroid-Triggered Hypokalemic Periodic Paralysis in a Patient With Treated Hypothyroidism (2026) · cites this paper as [9]

Cites

1 retracted

Flagged first, then by citations

1 of the 154 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Wiersinga, W. M., Poppe, K. G., & Effraimidis, G.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Université Libre de Bruxelles (BE)
  • University of Thessaly (GR)
ORCID
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2023-04
Volume
11
Issue
4
Pages
282-298
ISSN
2213-8587 (ISSN-L)
DOI
10.1016/s2213-8587(23)00005-0
OpenAlex
W4321766463
Semantic Scholar
f3b4164bc2bb48249a703dd0658e104ae5a4fcfb
Cited by
254
References
154
Citations by year
2026: 76 · 2025: 85 · 2024: 75 · 2023: 18
FWCI
9.18
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Ophthalmology and Eye Disorders
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
Keywords
hyperthyroidism, Graves' disease, etiology, pathogenesis, diagnosis, antithyroid drug therapy, thyroidectomy, radiofrequency ablation, thyrotoxicosis, thyroid storm, thyrotoxic periodic paralysis, atrial fibrillation, pregnancy, COVID-19 pandemic, prognosis, mortality, B cell-targeted therapy
MeSH terms
COVID-19, COVID-19 Testing, Female, Goiter, Nodular, Graves Disease, Humans, Hyperthyroidism, Iodine Radioisotopes, Pregnancy, Prognosis, Antithyroid Agents, Thyrotropin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review